TT-01488 with rituximab for mantle cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new oral drug, TT-01488, taken with a standard antibody treatment (rituximab) for mantle cell lymphoma. It may help people who have either not been treated yet or whose cancer has returned, and aims to improve outcomes with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older (some groups require being 65 or older if you have certain health conditions).
- You have been diagnosed with mantle cell lymphoma that tests positive for CD20 and cyclin D1 or the t(11;14) genetic change.
- Your cancer is at stage II, III, or IV (meaning it has spread beyond one lymph node area).
- You have at least one measurable tumor that can be checked on scans.
- You are able to do most daily activities (ECOG performance status 0-2).
- Your organs (like heart, kidneys, lungs) are working well enough, and you are not on certain medications that could interfere with the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (acalabrutinib and rituximab) for people with mantle cell lymphoma who have not had treatment before. It is designed for older patients or younger patients with a less aggressive form of the disease.
This trial tests a new drug combination (pirtobrutinib plus rituximab) for people with mantle cell lymphoma who have not yet received any treatment and do not have symptoms. The goal is to see if the combination is safe and effective.
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
This trial tests a combination of three drugs (orelabrutinib, lisaftoclax, and rituximab) for people with mantle cell lymphoma who have not had treatment before and have high-risk features. The goal is to see if this combination works better than standard treatments.
This trial tests a new combination of two targeted drugs for people with mantle cell lymphoma that has not responded to or has returned after treatment with a BTK inhibitor. The drugs aim to block cancer cell growth and survival pathways to potentially control the disease.
This trial tests a new combination of medications for mantle cell lymphoma that has returned or not responded to other treatments. The goal is to see if this combination can shrink tumors and is safe for patients like you.
Hear when a new Mantle Cell Lymphoma (MCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.